Who are ARV-1801's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Teclistamab (Tec), Placebo+AK111, ABP 798, IMA203, CHS-0214, AK101.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/arv-1801.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

ARV-1801 — Competitive Intelligence Brief

ARV-1801 (ARV-1801) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bispecific T-cell engager (BiTE). Area: Oncology.

phase 2 Bispecific T-cell engager (BiTE) CD3 and tumor-associated antigen (specific target not publicly disclosed) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

ARV-1801 (ARV-1801) — Arrevus Inc.. ARV-1801 is a bispecific antibody that simultaneously engages T cells and tumor cells to redirect immune attack against cancer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ARV-1801 TARGET	ARV-1801	Arrevus Inc.	phase 2	Bispecific T-cell engager (BiTE)	CD3 and tumor-associated antigen (specific target not publicly disclosed)
Teclistamab (Tec)	Teclistamab (Tec)	University of Heidelberg Medical Center	marketed	Bispecific T-cell engager (BiTE)	CD3 and BCMA
Placebo+AK111	Placebo+AK111	Akeso	phase 3	Bispecific T-cell engager (BiTE)	CD3 and tumor-associated antigen (specific target not publicly disclosed)
ABP 798	ABP 798	Amgen	phase 3	Bispecific T-cell engager (BiTE)	CD3 / PMEL (gp100)
IMA203	IMA203	Immatics US, Inc.	phase 3	Bispecific T-cell engager (BiTE)	CD3 and PRAME
CHS-0214	CHS-0214	Coherus Oncology, Inc.	phase 3	Bispecific T-cell engager (BiTE)	CD3 and tumor-associated antigen (specific target not publicly disclosed)
AK101	AK101	Akeso	phase 3	Bispecific T-cell engager (BiTE)	CD3 / PSMA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bispecific T-cell engager (BiTE) class)

Akeso · 3 drugs in this class
Amgen · 2 drugs in this class
Arrevus Inc. · 1 drug in this class
Coherus Oncology, Inc. · 1 drug in this class
Immatics US, Inc. · 1 drug in this class
University of Heidelberg Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ARV-1801 — Competitive Intelligence Brief. https://druglandscape.com/ci/arv-1801. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab